Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,620 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Retinal Disorder Clear all
Recruiting Phase 2 Interventional

Retinoblastoma Phase II Expanded Access Clinical Trial

NCT06679634
View directory record Official record
Conditions
Retinoblastoma
Interventions
Chemoplaque also referred to as Episcleral Topotecan
Drug
Lead sponsor
Targeted Therapy Technologies, LLC
Industry
Eligibility
Up to 8 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
New York, New York • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 31, 2026, 11:42 AM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

NCT02718326
View directory record Official record
Conditions
Nonproliferative Diabetic Retinopathy
Interventions
Intravitreal aflibercept injection [IAI], Sham
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
71
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 31, 2026, 11:42 AM EDT
Completed Phase 2Phase 3 Interventional

Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)

NCT00305630
View directory record Official record
Conditions
Choroidal Neovascularization, Age-Related Macular Degeneration
Interventions
Periocular injection of triamcinolone acetonide 40mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Baltimore, Maryland • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 22, 2006 · Synced Oct 31, 2026, 11:42 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Carbidopa-Levodopa in Dry AMD With Geographic Atrophy

NCT03451500
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
carbidopa-levodopa
Drug
Lead sponsor
Snyder, Robert W., M.D., Ph.D., P.C.
Individual
Eligibility
50 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 31, 2026, 11:42 AM EDT
Terminated Phase 2 Interventional

Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD

NCT02467634
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
HuCNS-SC sub-retinal transplantation
Biological
Lead sponsor
StemCells, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Tucson, Arizona • Beverly Hills, California • Campbell, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Oct 31, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa

NCT04604899
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
human retinal progenitor cells
Biological
Lead sponsor
jCyte, Inc
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Irvine, California • Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 31, 2026, 11:42 AM EDT
Completed Not applicable Interventional Results available

Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival

NCT01640171
View directory record Official record
Conditions
Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel, Acuvail, Intra-vitreal Anti-VEGF Drug
Procedure · Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 31, 2026, 11:42 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy

NCT03403699
View directory record Official record
Conditions
Diabetes Complications, Diabetic Retinopathy
Interventions
Generation of inducible pluripotent stem cells
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 98 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 11:42 AM EDT
Terminated No phase listed Observational

Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases

NCT02688309
View directory record Official record
Conditions
Macular Edema, Fibrosis of the Retina
Interventions
Ozurdex, Surgery, Anterior Chamber (AC) Tap
Drug · Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 31, 2026, 11:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Object Finder for a Retinal Prosthesis

NCT04319809
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Object recognition subsystem
Device
Lead sponsor
Minnesota HealthSolutions
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 31, 2026, 11:42 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema

NCT04697758
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg
Drug
Lead sponsor
AsclepiX Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Gilbert, Arizona • Los Angeles, California • St. Petersburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 31, 2026, 11:42 AM EDT
Completed Early Phase 1 Interventional

Photobiomodulation for the Treatment of Diabetic Macular Edema

NCT02457975
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
670nm PBM, intravitreous VEGF-inhibitors
Device · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 31, 2026, 11:42 AM EDT
Completed Phase 3 Interventional Results available

Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study

NCT00604383
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
ruboxistaurin, placebo
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 31, 2026, 11:42 AM EDT
Terminated Phase 1Phase 2 Interventional

Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)

NCT04120883
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Hydroxychloroquine lower dose, Hydroxychloroquine higher dose
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 31, 2026, 11:42 AM EDT
Not listed Phase 4 Interventional

Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept

NCT03468296
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Intravitreal Aflibercept Injection 2mg
Drug
Lead sponsor
Tennessee Retina
Other
Eligibility
50 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 31, 2026, 11:42 AM EDT
Completed No phase listed Observational

High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degeneration

NCT00656903
View directory record Official record
Conditions
Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 31, 2026, 11:42 AM EDT
Completed Phase 1 Interventional

A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes

NCT00001062
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 31, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)

NCT00729846
View directory record Official record
Conditions
Age Related Macular Degeneration, Choroidal Neovascularization, Macular Edema
Interventions
Bevacizumab, verteporfin photodynamic therapy reduced fluence, verteporfin photodynamic therapy standardfluence
Drug · Device
Lead sponsor
California Retina Consultants
Other
Eligibility
50 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Bakersfield, California • Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2016 · Synced Oct 31, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

Non-proliferative Diabetic Retinopathy Treated With Runcaciguat

NCT04722991
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Runcaciguat (BAY1101042), Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Modesto, California • Lakeland, Florida • Pinellas Park, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 31, 2026, 11:42 AM EDT
Completed No phase listed Observational

The Natural History and Pathogenesis of Mucolipidosis Type IV

NCT00015782
View directory record Official record
Conditions
Mucolipidosis Type IV
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 31, 2026, 11:42 AM EDT
Recruiting Phase 3 Interventional

Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

NCT05844982
View directory record Official record
Conditions
Radiation Retinopathy, Visual Impairment
Interventions
Faricimab, fluocinolone acetonide
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
29
States / cities
Palo Alto, California • Manchester, Connecticut • Tampa, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 31, 2026, 11:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

NCT06789445
View directory record Official record
Conditions
Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome, Inherited Retinal Disease (IRD), Rod-Cone Dystrophy, Rod-Cone Disease, Retinal Degeneration, Cone-Rod Disease (C-RD), Cone-Rod Dystrophy
Interventions
OpCT-001
Biological
Lead sponsor
BlueRock Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 11:42 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion

NCT01277302
View directory record Official record
Conditions
Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
42
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 31, 2026, 11:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Intravitreal Injection Site and Perceived Pain

NCT05640895
View directory record Official record
Conditions
Pain
Interventions
Intravitreal injection site
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 100 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 31, 2026, 11:42 AM EDT